Peptide May Help Predict No-Reflow Phenomenon
Angiographic 'no-reflow phenomenon' can occur after stent placement for myocardial infarction
MONDAY, Aug. 27 (HealthDay News) -- N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) may predict no-reflow phenomenon after primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction, according to a report in the Aug. 15 issue of the American Journal of Cardiology.
Seo Na Hong, M.D., of Chonnam National University Hospital in Gwangju, South Korea, and colleagues studied 159 patients with acute ST-elevation myocardial infarction. Blood samples taken before patients underwent percutaneous coronary intervention were analyzed for NT-pro-BNP.
The researchers found that NT-pro-BNP over 500 picograms per milliliter was associated with a high probability of no-reflow phenomenon (odds ratio, 4.42). This problem is linked with larger infarct size and poorer recovery from myocardial infarction.
"The no-reflow phenomenon remains an independent predictor of death in a wide group of patients treated with percutaneous coronary intervention, not only those with ST-elevation myocardial infarction," the authors write. "This study showed that NT-pro-BNP can be a useful predictor of no-reflow phenomenon in patients with acute ST-elevation myocardial infarction."